Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Evaluation and optimization of lipid nanoparticle-mediated prime editing in vivo
EF 2022-23
Résumé
Genetic diseases are among the most prevalent causes of death and disability worldwide, with estimates of over 7000 diseases affecting up to 10% of the global population. Only 5% of genetic diseases have approved therapeutic treatments, resulting in a largely unmet healthcare need. An emerging solution to this is prime editing (PE), a recently developed gene editing technology with the potential to correct 89% of known disease-causing mutations. However, delivering the PE machinery to cells within the body remains a key challenge for therapeutic use. Lipid nanoparticles (LNPs) delivering gene editing components in the form of ribonucleic acid (RNA) provide a safe and effective delivery method, but no research has been published investigating LNP-mediated PE in vivo. The aim of this project is to perform initial in vivo evaluation and optimization experiments for LNP-mediated PE, using clinically approved LNP components for delivery to the liver. This will utilize a novel reporter mouse model developed by our lab that couples successful gene editing with the production of a bioluminescent signal, allowing direct observation of both the efficacy and location of PE. Following an initial assessment of LNP-mediated PE, editing efficiency will be optimized through the alteration of the RNA cargo encoding the PE machinery. Factors such as the amount of RNA present within the LNP, as well as the incorporation of modifications that promote RNA stability will be assessed. These initial evaluation and optimization experiments will provide a first step towards the development of safe and effective PE therapeutics, which could provide treatment for the millions of individuals suffering from untreated genetic diseases across Canada and worldwide.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486211
Name
Thomson Tyler A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation and optimization of lipid nanoparticle-mediated prime editing in vivo
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Base Editing; Crispr/Cas9; Gene Delivery; Gene Editing; Gene Therapy; Genetic Disease; Lipid Nanoparticles; Nanomedicine; Prime Editing
Abstract
Genetic diseases are among the most prevalent causes of death and disability worldwide, with estimates of over 7000 diseases affecting up to 10% of the global population. Only 5% of genetic diseases have approved therapeutic treatments, resulting in a largely unmet healthcare need. An emerging solution to this is prime editing (PE), a recently developed gene editing technology with the potential to correct 89% of known disease-causing mutations. However, delivering the PE machinery to cells within the body remains a key challenge for therapeutic use. Lipid nanoparticles (LNPs) delivering gene editing components in the form of ribonucleic acid (RNA) provide a safe and effective delivery method, but no research has been published investigating LNP-mediated PE in vivo. The aim of this project is to perform initial in vivo evaluation and optimization experiments for LNP-mediated PE, using clinically approved LNP components for delivery to the liver. This will utilize a novel reporter mouse model developed by our lab that couples successful gene editing with the production of a bioluminescent signal, allowing direct observation of both the efficacy and location of PE. Following an initial assessment of LNP-mediated PE, editing efficiency will be optimized through the alteration of the RNA cargo encoding the PE machinery. Factors such as the amount of RNA present within the LNP, as well as the incorporation of modifications that promote RNA stability will be assessed. These initial evaluation and optimization experiments will provide a first step towards the development of safe and effective PE therapeutics, which could provide treatment for the millions of individuals suffering from untreated genetic diseases across Canada and worldwide.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thomson, Tyler A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~